Iterum Therapeutics Stock Forecast, Price & News

+0.00 (+0.02 %)
(As of 09/16/2021 02:52 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume7,145 shs
Average Volume16.33 million shs
Market Capitalization$110.36 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ITRM News and Ratings via Email

Sign-up to receive the latest news and ratings for Iterum Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Iterum Therapeutics logo

About Iterum Therapeutics

Iterum Therapeutics Plc operates as a pharmaceutical company, which engages in the development and commercialization of sulopenem to be potentially the first and only oral and intravenous (IV) branded penem available. The company was founded by Corey N. Fishman on June 24, 2015 and is headquartered in Dublin, Ireland.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.40 out of 5 stars

Medical Sector

1073rd out of 1,352 stocks

Pharmaceutical Preparations Industry

523rd out of 665 stocks

Analyst Opinion: 2.9Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Iterum Therapeutics (NASDAQ:ITRM) Frequently Asked Questions

Is Iterum Therapeutics a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iterum Therapeutics in the last twelve months. There are currently 1 sell rating and 3 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Iterum Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ITRM, but not buy additional shares or sell existing shares.
View analyst ratings for Iterum Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Iterum Therapeutics?

Wall Street analysts have given Iterum Therapeutics a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Iterum Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Iterum Therapeutics?

Iterum Therapeutics saw a decrease in short interest in the month of August. As of August 31st, there was short interest totaling 2,570,000 shares, a decrease of 45.1% from the August 15th total of 4,680,000 shares. Based on an average daily trading volume, of 11,650,000 shares, the days-to-cover ratio is presently 0.2 days. Approximately 1.5% of the company's shares are short sold.
View Iterum Therapeutics' Short Interest

When is Iterum Therapeutics' next earnings date?

Iterum Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, November 15th 2021.
View our earnings forecast for Iterum Therapeutics

How were Iterum Therapeutics' earnings last quarter?

Iterum Therapeutics plc (NASDAQ:ITRM) released its quarterly earnings results on Thursday, August, 12th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.02.
View Iterum Therapeutics' earnings history

How has Iterum Therapeutics' stock been impacted by COVID-19?

Iterum Therapeutics' stock was trading at $2.03 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ITRM stock has decreased by 70.4% and is now trading at $0.6001.
View which stocks have been most impacted by COVID-19

What price target have analysts set for ITRM?

4 equities research analysts have issued 1 year price objectives for Iterum Therapeutics' stock. Their forecasts range from $0.69 to $1.50. On average, they anticipate Iterum Therapeutics' share price to reach $0.96 in the next twelve months. This suggests a possible upside of 60.5% from the stock's current price.
View analysts' price targets for Iterum Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Iterum Therapeutics' key executives?

Iterum Therapeutics' management team includes the following people:
  • Corey N. Fishman, President, Chief Executive Officer & Director
  • Tom Loughman, Senior Vice President-Technical Operations
  • Judith M. Matthews, Chief Financial Officer
  • Steven Aronin, Senior Vice President & Head-Clinical Development
  • Louise Barrett, Senior Vice President-Legal Affairs

Who are some of Iterum Therapeutics' key competitors?

What other stocks do shareholders of Iterum Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Iterum Therapeutics investors own include Aeglea BioTherapeutics (AGLE), Viking Therapeutics (VKTX), Acasti Pharma (ACST), Axsome Therapeutics (AXSM), Innovate Biopharmaceuticals (INNT), OPKO Health (OPK), VYNE Therapeutics (VYNE), Fulcrum Therapeutics (FULC), (NINE) and Ocugen (OCGN).

When did Iterum Therapeutics IPO?

(ITRM) raised $80 million in an initial public offering on Friday, May 25th 2018. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. Leerink Partners and RBC Capital Markets served as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers.

What is Iterum Therapeutics' stock symbol?

Iterum Therapeutics trades on the NASDAQ under the ticker symbol "ITRM."

Who are Iterum Therapeutics' major shareholders?

Iterum Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (1.84%), Millennium Management LLC (1.43%), QS Investors LLC (0.21%), Grimes & Company Inc. (0.08%), Focused Wealth Management Inc (0.06%) and Cubist Systematic Strategies LLC (0.05%). Company insiders that own Iterum Therapeutics stock include Alexander J Denner, Corey N Fishman, Judith M Matthews, Michael W Dunne and Sofinnova Venture Partners Ix,.
View institutional ownership trends for Iterum Therapeutics

Which institutional investors are selling Iterum Therapeutics stock?

ITRM stock was sold by a variety of institutional investors in the last quarter, including Insight Advisors LLC PA, Citadel Advisors LLC, National Asset Management Inc., Squarepoint Ops LLC, Morgan Stanley, and Morgan Stanley. Company insiders that have sold Iterum Therapeutics company stock in the last year include Alexander J Denner, Corey N Fishman, Judith M Matthews, and Michael W Dunne.
View insider buying and selling activity for Iterum Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Iterum Therapeutics stock?

ITRM stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Millennium Management LLC, QS Investors LLC, Cubist Systematic Strategies LLC, Susquehanna Fundamental Investments LLC, Focused Wealth Management Inc, Grimes & Company Inc., and Sigma Planning Corp.
View insider buying and selling activity for Iterum Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Iterum Therapeutics?

Shares of ITRM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Iterum Therapeutics' stock price today?

One share of ITRM stock can currently be purchased for approximately $0.60.

How much money does Iterum Therapeutics make?

Iterum Therapeutics has a market capitalization of $109.68 million and generates $40,000.00 in revenue each year. The company earns $-52,010,000.00 in net income (profit) each year or ($1.40) on an earnings per share basis.

How many employees does Iterum Therapeutics have?

Iterum Therapeutics employs 7 workers across the globe.

What is Iterum Therapeutics' official website?

The official website for Iterum Therapeutics is

Where are Iterum Therapeutics' headquarters?

Iterum Therapeutics is headquartered at BLOCK 2 FLOOR 3 HARCOURT CENTRE HARCOURT STREET, DUBLIN L2, 2.

How can I contact Iterum Therapeutics?

Iterum Therapeutics' mailing address is BLOCK 2 FLOOR 3 HARCOURT CENTRE HARCOURT STREET, DUBLIN L2, 2. The company can be reached via phone at (531) 903-8920 or via email at [email protected]

This page was last updated on 9/16/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.